Global B-Cell Lymphoma Treatment Market Size, Share & Trends Analysis Report, By Type (Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System (CNS) Lymphoma, Primary Intraocular Lymphoma, and Others), Stages (Stage I, Stage II , Stage III, Stage IV, and Others), Treatment (Radiation, Chemotherapy, Immune Therapy, Stem Cell Transplant, and Others), By End-Users (Hospitals, Specialty Clinics, Home Healthcare, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The global B-cell lymphoma treatment market is anticipated to grow at a CAGR of 7.5% during the forecast period (2022-2028). B-cell lymphoma is a rare form of non-Hodgkin lymphoma. It is a form of blood cancer that impacts white blood cells known as lymphocytes. The pivotal factors that are driving the market growth include an increase in the number of population base suffering from B-cell lymphoma coupled with the rise in the R&D activities in the healthcare sector resulting in a favorable product pipeline. As per the American Cancer Society about 3 out of 4 people will have no signs of disease after the initial treatment, while many get cured. However, about 700 people in the US are diagnosed with hairy cell leukemia (which is rare in this case), each year. The market is majorly driven by the growing number of clinical trials as well as the growing approvals by various governmental agencies.

 

As per the study published in Cancer Journal for Clinicians, in 2016 3,320 new cases of B-cell lymphoma were diagnosed in the US. Approvals for various new drugs by federal agencies is expected to drive the global B-cell lymphoma treatment market. For instance, in May 2018, the FDA approved AstraZeneca’s Calquence (Acalabrutinib) for relapsed or refractory B-cell lymphoma in adults. The B-cell lymphoma treatment market is also driven by development of targeted therapy drugs with low toxicity in combination with approved drugs for the treatment of relapsed B-cell lymphoma.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Stages
  • By Treatment
  • By End-User
  • By Distribution Channel
• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Novartis International AG, F. Hoffman La-Roche Ltd., and AbbVie Inc., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global B-Cell Lymphoma Treatment Market Report by Segment

By Type

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Lymphoplasmacytic Lymphoma
• Hairy Cell Leukemia
• Primary Central Nervous System (CNS) Lymphoma
• Primary Intraocular Lymphoma
• Others

 

By Stages

• Stage I
• Stage II
• Stage III
• Stage IV
• Others

 

By Treatment

• Radiation
• Chemotherapy
• Immune Therapy
• Stem Cell Transplant
• Others

 

By End-Users

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

 

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

 

Global B-Cell Lymphoma Treatment Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

 

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

 

Rest of the World

• Latin America
• Middle East and Africa